Searched for
GENERIC ALBUTEROL SULFATE INHALATION AEROSOL
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analysts- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analysts
- In 1987, the world swapped ozone-destroying CFCs for safer refrigerants; nearly 40 years later, scientists found the switch had been quietly raining a forever chemical across the planet
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 27% in 1 yearAfter the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...01 Jun, 2026, 01.29 PM IST
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...31 May, 2026, 01.34 PM IST
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...29 May, 2026, 05.30 AM IST
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...29 May, 2026, 12.57 AM IST
- Hantavirus scare a wake-up call: Why India must build its disease X defencesA recent hantavirus outbreak on a cruise ship echoes past pandemic scares. Experts warn Disease X, a future unknown pathogen, is a near cer...24 May, 2026, 11.21 PM IST
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...24 May, 2026, 04.23 PM IST
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...23 May, 2026, 10.24 PM IST
- That dusty cabin you're opening this weekend could be hiding a deadly virusSpring cleaning at cabins can be dangerous. Hantavirus, carried by mice, spreads through droppings and urine. Inhaling dust from these can ...11 May, 2026, 04.08 PM IST
- Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosolPharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks...23 Apr, 2026, 01.38 PM IST
- US unit of India's Cipla recalls six batches of bronchospasm inhalerIndian pharmaceutical company Cipla has recalled six batches of its Albuterol Sulfate HFA Inhalation Aerosol in the US due to a container d...07 Jul, 2023, 10.36 AM IST
- Lupin inks pact to acquire two inhalation brands from Sunovion for USD 75 mnThe acquisition of these two brands will expand the company's inhalation product portfolio in the US and strengthen its presence in the res...20 Oct, 2022, 10.38 AM IST
- Pharma sector to remain a market favourite due to earnings visibility, say analystsThe sector will remain a market favourite due to earnings visibility, which does not exist for most sectors currently because of the pandem...19 Sep, 2020, 10.00 AM IST
- Pharma’s perennial underperformer gets a shot in the arm. Can it deliver?The stock has gained 64 per cent from March lows and 27 per cent year to date, but still 54 per cent down from its all-time high of Rs 2,12...26 Aug, 2020, 05.07 PM IST
- Lupin gets US health regulator's approval for asthmatic symptoms prevention drugThe approved product is a generic version of ProAir HFA of Teva Branded Pharmaceutical Products R&D, Inc. In a regulatory filing, Lupin sai...25 Aug, 2020, 10.45 AM IST
- Buy Cipla, target price Rs 668: ICICI SecuritiesThe brokerage has raised FY21-FY22 EPS estimates by 11-12 per cent on generic Proventil approval and the increase in Rs/$ rate to 74 from 7...13 Apr, 2020, 12.08 PM IST
- Cipla hits 15% upper circuit as USFDA gives final approval to Albuterol Inhalation AerosolFollowing the development, the scrip hit its 15 per cent upper circuit limit at Rs 589.95.09 Apr, 2020, 03.47 PM IST
- Cipla gets final approval from USFDA for Albuterol Sulfate Inhalation AerosolIn a regulatory filing the company said "it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfa...09 Apr, 2020, 01.14 PM IST
Load More
